Cells (Mar 2024)

Fluvastatin Converts Human Macrophages into Foam Cells with Increased Inflammatory Response to Inactivated <i>Mycobacterium tuberculosis H37Ra</i>

  • María Teresa Montero-Vega,
  • Joaquín Matilla,
  • Eulalia Bazán,
  • Diana Reimers,
  • Ana De Andrés-Martín,
  • Rafael Gonzalo-Gobernado,
  • Carlos Correa,
  • Francisco Urbano,
  • Diego Gómez-Coronado

DOI
https://doi.org/10.3390/cells13060536
Journal volume & issue
Vol. 13, no. 6
p. 536

Abstract

Read online

Cholesterol biosynthesis inhibitors (statins) protect hypercholesterolemic patients against developing active tuberculosis, suggesting that these drugs could help the host to control the pathogen at the initial stages of the disease. This work studies the effect of fluvastatin on the early response of healthy peripheral blood mononuclear cells (PBMCs) to inactivated Mycobacterium tuberculosis (Mtb) H37Ra. We found that in fluvastatin-treated PBMCs, most monocytes/macrophages became foamy cells that overproduced NLRP3 inflammasome components in the absence of immune stimulation, evidencing important cholesterol metabolism/immunity connections. When both fluvastatin-treated and untreated PBMCs were exposed to Mtb H37Ra, a small subset of macrophages captured large amounts of bacilli and died, concentrating the bacteria in necrotic areas. In fluvastatin-untreated cultures, most of the remaining macrophages became epithelioid cells that isolated these areas of cell death in granulomatous structures that barely produced IFNγ. By contrast, in fluvastatin-treated cultures, foamy macrophages surrounded the accumulated bacteria, degraded them, markedly activated caspase-1 and elicited a potent IFNγ/cytotoxic response. In rabbits immunized with the same bacteria, fluvastatin increased the tuberculin test response. We conclude that statins may enhance macrophage efficacy to control Mtb, with the help of adaptive immunity, offering a promising tool in the design of alternative therapies to fight tuberculosis.

Keywords